217 related articles for article (PubMed ID: 31206365)
21. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
22. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
[TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
[TBL] [Abstract][Full Text] [Related]
25. High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer.
Gennaro M; Meneghini E; Baili P; Bravaccini S; Curcio A; De Santis MC; Lozza L; Listorti C; Di Cosimo S; Sant M; Folli S
Tumori; 2020 Feb; 106(1):64-69. PubMed ID: 31446852
[TBL] [Abstract][Full Text] [Related]
26. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
27. The long-term psychosocial consequences of screen-detected ductal carcinoma in situ and invasive breast cancer.
Gram EG; Manso TFR; Heleno B; Siersma V; Á Rogvi J; Brodersen JB
Breast; 2023 Aug; 70():41-48. PubMed ID: 37307773
[TBL] [Abstract][Full Text] [Related]
28. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; Gommers S; Siesling S; van Nijnatten TJA; Smidt ML
Breast Cancer Res Treat; 2023 Sep; 201(2):227-235. PubMed ID: 37395816
[TBL] [Abstract][Full Text] [Related]
29. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
30. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
[TBL] [Abstract][Full Text] [Related]
31. Human Papillomavirus (HPV) Detection by Chromogenic In Situ Hybridization (CISH) and p16 Immunohistochemistry (IHC) in Breast Intraductal Papilloma and Breast Carcinoma.
Guo H; Idrovo JP; Cao J; Roychoudhury S; Navale P; Auguste LJ; Bhuiya T; Sheikh-Fayyaz S
Clin Breast Cancer; 2021 Dec; 21(6):e638-e646. PubMed ID: 34059433
[TBL] [Abstract][Full Text] [Related]
32. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer.
Zhang W; Gao EL; Zhou YL; Zhai Q; Zou ZY; Guo GL; Chen GR; Zheng HM; Huang GL; Zhang XH
World J Surg Oncol; 2012 Dec; 10():262. PubMed ID: 23216911
[TBL] [Abstract][Full Text] [Related]
33.
Zhang Z; Wang H; Jin Y; Zhou J; Chu C; Tang F; Zou L; Zou Q
Biomark Med; 2023 Jun; 17(12):553-562. PubMed ID: 37814985
[No Abstract] [Full Text] [Related]
34. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery.
Langhans L; Jensen MB; Talman MM; Vejborg I; Kroman N; Tvedskov TF
JAMA Surg; 2017 Apr; 152(4):378-384. PubMed ID: 28002557
[TBL] [Abstract][Full Text] [Related]
35. Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study.
van Deurzen CH
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):627-633. PubMed ID: 27590331
[TBL] [Abstract][Full Text] [Related]
36. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
[TBL] [Abstract][Full Text] [Related]
37. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T
Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
[TBL] [Abstract][Full Text] [Related]
39. Clinic-Pathological Features of Breast Ductal Carcinoma
Zheng J; Zhou T; Li F; Shi J; Zhang L
Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
[No Abstract] [Full Text] [Related]
40. miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
Woo JW; Choi HY; Kim M; Chung YR; Park SY
Breast Cancer; 2022 Sep; 29(5):814-824. PubMed ID: 35451796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
